CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (FMRP) (Institutional affiliation from the last research proposal) Birthplace: Inglaterra
Graduated from the University of London, UK, with a Masters in Genetics and a PhD in Medical Biophysics from the University of Toronto. Postdoc at Northwick Park Hospital, Harrow, UK (1988). Was director of Molecular Pathology, Hospital for Sick Children in Toronto (1989-1997). Professor in 2001 in the Department of Pathology at Queen's University in Kingston, Canada and Director of the Laboratory of Translational Research, NCIC - Clinical Trials Group (2008-13). He was visiting professor at the Cancer Hospital of São Paulo (AC Camargo) in the period 2006-2007 and of Barretos Cancer Hospital in 2011 is currently a Professor in the Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, where he developed a project in collaboration with the Departments of Genetics and Surgery. The current research projects involve investigation of the PTEN gene in prostate cancer. Research Productivity Grant Level PQ-1D. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The therapeutic landscape of advanced prostate cancer has considerably broadened in recent years. With the implementation of sensitive functional imaging techniques, advanced prostate cancer is no longer limited to metastatic castrate-resistant disease, but now also includes metastatic hormone-sensitive prostate cancer and some localized tumors that have previously unrecognized occult met…
Immunotherapy has improved patient survival in many types of cancer, but in prostate cancer (PCa) initial results with immunotherapy have been disappointing. This tumor is considered immunologically "cold" and unable to generate an effective T-cell response against cancer cells. However, a small but significant percentage of patients with PCa do respond to immunotherapy for reasons that a…
Prostate cancer is characterized by a high incidence, great variation in the length of the latent period and uncertainty in the outcome. Moreover, blood PSA screening has resulted in over-diagnosis, so that many patients have clinically insignificant disease. Currently, treatment at first diagnosis is based on predictive nomograms, which integrate detailed histopathology with clinical dat…
Prostate cancer (PCa) is the most commonly diagnosed malignant tumor in men and the second leading cause of cancer-related mortality. Despite the high long-term survival in localized prostate cancer, metastatic disease remains largely incurable even after intensive multimodal therapy. Even with immunotherapy, which has improved patient survival in many types of cancers, PCa results have b…
Prostate cancer (PCa) is the most commonly diagnosed malignant tumor in men and the second leading cause of cancer-related mortality. Despite the high long-term survival in localized prostate cancer, metastatic disease remains largely incurable even after intensive multimodal therapy. Even with immunotherapy, which has improved patient survival in many types of cancers, PCa results have b…
Background: Treatment of advanced PCa remains a therapeutic challenge. Moreover, new immunotherapies like immune-checkpoint blockade (ICB) have shown significant benefits in only a minority of patients. CDK12 defect-PCa is a recently discovered molecular subtype of this tumor with a high neoantigen load and increased immune cell infiltrate. CDK12 defective PCa has variable results with re…
Background: The first-line treatment for Prostate Cancer (PCa) patients is androgen deprivation therapy (ADT). Immunotherapy usually fails because PCa is an immunologically cold tumor. In 50% of PCa ETS gene is highly expressed because of fusion with the androgen-responsive TMPRSS2 gene. We have shown that PTEN loss may be involved in immune evasion in PCa. ETS overexpression induces di…
Prostate cancer (PCa) is the sixth most common type of cancer in the world and is also the most prevalent in men. Our preliminary data showed that there is increased expression of STAT1 and decreased STAT3 expression in PCa tumors with deletion of the PTEN gene. Since the STAT transcription factor family is involved in modulating immune response, this observation suggests that the inflam…
We evaluated 493 PCa cases from the Genomic Data Commons cohort using aCGH and RNAseq data through an in silico analysis and found that 124 from 449 genes related to immune and inflammatory responses were differentially expressed between PTEN loss (n=104) versus PTEN intact (n=398) cases. We have demonstrated that the 124 differentially expressed genes were associated with type I and II i…
| 1 / 1 | Ongoing grants |
| 2 / 2 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 3 / 3 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 9 / 9 | All research grants and scholarships |
| Associated processes | |